Sanofi, Regeneron Drug Fails Covid Testing
Meanwhile, Paris-based Sanofi (SNY) late Monday said a Phase 3 trial of its drug Kevzara to treat severely or critically ill Covid-19 patients had failed.
Sanofi and U.S.-based Regeneron Pharmaceuticals (REGN) collaborate on Kevzara. It treats adults with moderate to severe rheumatoid arthritis who have not responded to or tolerated previous therapy.
https://finance.yahoo.com/m/2ea448ac-e772-3db9-8699-8b4a8fc0be38/covid-roundup-astrazeneca.html
Severe Covid patients eyes on MSB, while one potential choices drop out.
Cell Therapy News/Articles, page-6229
-
- There are more pages in this discussion • 12,203 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.020(1.50%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.40 | $1.34 | $3.562M | 2.615M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 17969 | 2 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |